Transplantation for multiple myeloma: who, when, how often?
Open accessAbstract
Controversy in hematologyTransplantation for multiple myeloma: who, when, how often? High-dose therapy in multiple myeloma Joan Blade ´The outcome of patients with multiple myeloma (MM) is unsatisfactory, with a median survival of less than 3 years.1,2 The prospects for survival at 10 years are poor with conventional chemotherapy.3,4 The limited efficacy of conventional treatment prompted the introduction of high-dose therapy (HDT) followed by stem cell support in an attempt to achieve a greater tumor reduction with longer disease-free and overall survival (OS).Not all patients in whom HDT is feasible obtain a significant benefit from the procedure.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ASCT improves median overall survival in multiple myeloma by about 12 months.
“ASCT improves median OS in multiple myeloma by approximately 12 months.125–128”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [127]
The take-home message (p. 7) reports a 12–15-month survival benefit from transplantation, and Consolidation of initial therapy (p. 3) reports 12 months longer overall survival in the high-dose treatment group of the MRC analysis. The paper limits its clear survival-benefit conclusion to patients younger than 60–65 with reasonable renal function; the citing sentence omits that qualification and generalizes to multiple myeloma patients overall. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164 · see citing works
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768 · see citing works
Bladé, J., Samson, D., Reece, D. E., Apperley, J. F., Björkstrand, B., Gahrton, G., Gertz, M. A., Giralt, S. A., Jagannath, S., & Vesole, D. H. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,516 · see citing works
Self-citationCollins, R. H., Shpilberg, O., Drobyski, W. R., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.433 · Cited by 1,261 · see citing works
Moreau, P. (2002) · Blood · doi:10.1182/blood.v99.3.731 · Cited by 568 · see citing works
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542 · see citing works
Graft-versus-myeloma effect: proof of principle
Tricot, G. J. K., Vesole, D., Jagannath, S., Hilton, J., Munshi, N. C., & Barlogie, B. (1996) · Blood · doi:10.1182/blood.v87.3.1196.bloodjournal8731196 · Cited by 542 · see citing works
Self-citationHIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
McElwain, T. J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 514 · see citing works
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D. H., Siegel, D. S. D., Tricot, G. J. K., Munshi, N. C., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55.401k04_55_65 · Cited by 502 · see citing works
Self-citationPasquali, S., Maqueo, J. D., Vela, J. E., Kyle, R. A., Leong, T. L., Fritz, E., Suciu, S., PALVA, I. P., Oivanen, T. M., Corrado, C., et al. (1998) · Journal of Clinical Oncology · Cited by 470 · see citing works
Self-citationReichardt, V. L., Okada, C. Y., Liso, A., et al. (1999) · Blood · doi:10.1182/blood.v93.7.2411 · Cited by 390 · see citing works
Renal Failure in Multiple Myeloma
Bladé, J., Fernández‐Llama, P., Bosch, F., Montoliu, J., Lens, X. M., Montoto, S., Cases, A., Darnell, A., Rozmán, C., & Montserrat, E. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.17.1889 · Cited by 381 · see citing works
Self-citationBjörkstrand, B., Ljungman, P. T., Svensson, H., Hermans, J., Alegre, A. M., Apperley, J. F., Bladé, J., Carlson, K. E., Cavo, M., Ferrant, A., et al. (1996) · Blood · doi:10.1182/blood.v88.12.4711.bloodjournal88124711 · Cited by 355 · see citing works
Self-citationGahrton, G., Svensson, H., Cavo, M., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02726.x · Cited by 341 · see citing works
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma
Barlogie, B., Hall, R., Zander, A., Dicke, K. A., & Alexanian, R. (1986) · Blood · doi:10.1182/blood.v67.5.1298.1298 · Cited by 336 · see citing works
Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome
Singer, J. W., Buckner, C. D., Anasetti, C., et al. (1996) · Blood · doi:10.1182/blood.v88.7.2787.bloodjournal8872787 · Cited by 320 · see citing works
Lenhoff, S., Hjorth, M., Holmberg, E. C., Turesson, I., Westin, J., Nielsen, J. L., Wislöff, F., Brinch, L., Carlson, K. E., Carlsson, M. S., et al. (2000) · PubMed · doi:10.1182/blood.v95.1.7 · Cited by 310 · see citing works
Results of autologous stem cell transplant in multiple myeloma patients with renal failure
Badros, A. Z., Barlogie, B., Siegel, E. R., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03033.x · Cited by 308 · see citing works
Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma.
Gahrton, G., Tura, S., Ljungman, P. T., et al. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1312 · Cited by 290 · see citing works
Lokhorst, H. M., Schattenberg, A. V. M. B., Cornelissen, J. J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.3031 · Cited by 287 · see citing works
Barlogie, B., Alexanian, R., Ka, D., et al. (1987) · Blood · doi:10.1182/blood.v70.3.869.869 · Cited by 268 · see citing works
Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma
Siegel, D. S. D., Desikan, K. R., Mehta, J., Singhal, S., Fassas, A., Munshi, N. C., Anaissie, E. J., Naucke, S., Ayers, D. M., Spoon, D., et al. (1999) · Blood · doi:10.1182/blood.v93.1.51 · Cited by 239 · see citing works
Self-citationAutologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
Badros, A. Z., Barlogie, B., Siegel, E. R., Morris, C., Desikan, R. K., Zangari, M., Fassas, A., Anaissie, E. J., Munshi, N. C., & Tricot, G. J. K. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02976.x · Cited by 226 · see citing works
[Renal failure in multiple myeloma].
Sicinski, A. M. (1986) · PubMed · Cited by 223 · see citing works
Stewart, A. K., Vescio, R. A., Schiller, G. J., Ballester, O., Noga, S. J., Rugo, H. S., Freytes, C. O., Stadtmauer, E. A., Tarantolo, S., Sahebi, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.17.3771 · Cited by 198 · see citing works
Badros, A. Z., Barlogie, B., Morris, C. L., et al. (2001) · Blood · doi:10.1182/blood.v97.9.2574 · Cited by 188 · see citing works
Kröger, N. M., Sayer, H. G., Schwerdtfeger, R., et al. (2002) · Blood · doi:10.1182/blood-2002-04-1150 · Cited by 187 · see citing works
Badros, A. Z. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1295 · Cited by 181 · see citing works
Donor leukocyte infusions for multiple myeloma
Salama, M., Nevill, T. J., Marcellus, D. C., et al. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702685 · Cited by 178 · see citing works
Martinelli, G., Terragna, C., Zamagni, E., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2273 · Cited by 171 · see citing works
Vescio, R. A., Schiller, G. J., Stewart, A. K., Ballester, O., Noga, S. J., Rugo, H. S., Freytes, C. O., Stadtmauer, E. A., Tarantolo, S., Sahebi, F., et al. (1999) · PubMed · Cited by 168 · see citing works
Autotransplants in multiple myeloma: what have we learned?
Vesole, D., Tricot, G. J. K., Jagannath, S., Desikan, K. R., Siegel, D. S. D., Bracy, D., Miller, L., Cheson, B. D., Crowley, J. J., & Barlogie, B. (1996) · Blood · doi:10.1182/blood.v88.3.838.bloodjournal883838 · Cited by 166 · see citing works
Self-citationVesole, D., Barlogie, B., Jagannath, S., et al. (1994) · Blood · doi:10.1182/blood.v84.3.950.950 · Cited by 163 · see citing works
Self-citationLong-Term Survival in Multiple Myeloma
Kyle, R. A. (1983) · New England Journal of Medicine · doi:10.1056/nejm198302103080604 · Cited by 144 · see citing works
Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma
Giralt, S. A., Aleman, A., Anagnostopoulos, Α., et al. (2002) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703652 · Cited by 138 · see citing works
Mehta, J., Tricot, G. J. K., Jagannath, S., et al. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701208 · Cited by 136 · see citing works
Salmon, S. E., Crowley, J. J., Grogan, T. M., et al. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2405 · Cited by 135 · see citing works
Impact of complete remission with intensive therapy in patients with responsive multiple myeloma
Alexanian, R., Weber, D., Giralt, S. A., Dimopoulos, M. A., Delasalle, K. B., Smith, T., & Champlin, R. E. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703035 · Cited by 135 · see citing works
Dimopoulos, M. A., Alexanian, R., Przepiorka, D., Hester, J. P., Andersson, B. S., Giralt, S. A., Mehra, R. C., van Besien, K., Delasalle, K. B., & Reading, C. L. (1993) · Blood · doi:10.1182/blood.v82.8.2324.2324 · Cited by 127 · see citing works
Are myeloma patients with renal failure candidates for autologous stem cell transplantation?
Miguel, J. F. S., Lahuerta, J. J., García‐Sánz, R., et al. (2000) · The Hematology Journal · doi:10.1038/sj.thj.6200003 · Cited by 117 · see citing works
Early myeloablative therapy for multiple myeloma
Alexanian, R., Dimopoulos, M. A., Hester, J. P., et al. (1994) · Blood · doi:10.1182/blood.v84.12.4278.bloodjournal84124278 · Cited by 117 · see citing works
Michallet, M., Philip, T. O., Philip, I., Godinot, H., Sebban, C., Salles, G., Thiébaut, A., Biron, P., Lopez, F., Mazars, P., et al. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(00)00169-7 · Cited by 111 · see citing works
Singer, J. W., Rowley, S. D., Demirer, T., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1447 · Cited by 107 · see citing works
Tricot, G. J. K., Spencer, T., Sawyer, J. R., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03231.x · Cited by 90 · see citing works
Bladé, J., Miguel, J. F. S., Fontanillas, M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2167 · Cited by 89 · see citing works
Self-citationAlegre, A. M., Díaz-Mediavilla, J., Miguel, J. F. S., et al. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701062 · Cited by 85 · see citing works
Gulbrandsen, N., Wislöff, F., Brinch, L., Carlson, K. E., Dahl, I. M., Gimsing, P., Hippe, E., Hjorth, M., Knudsen, L. M., Lamvik, J. O., et al. (2001) · Medical Oncology · doi:10.1385/mo:18:1:65 · Cited by 85 · see citing works
Gahrton, G., Svensson, H., Björkstrand, B., Apperley, J. F., Carlson, K. E., Cavo, M., Ferrant, A., Fouillard, L., Gratecos, N., Gratwohl, A. A., et al. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701975 · Cited by 84 · see citing works
Singhal, S., Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., & Mehta, J. (2002) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703717 · Cited by 83 · see citing works
Vesole, D. H., Crowley, J. J., Catchatourian, R., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2173 · Cited by 78 · see citing works
Self-citationLemoli, R. M., Martinelli, G., Zamagni, E., et al. (2000) · Blood · doi:10.1182/blood.v95.7.2234 · Cited by 77 · see citing works
Fleming, M. D. (2003) · Blood · doi:10.1182/blood.v101.7.2473 · Cited by 76 · see citing works
Ballester, O., Tummala, R., Janssen, W. E., et al. (1997) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1700950 · Cited by 71 · see citing works
Blanc, R. L., Montminy-Métivier, S., Bélanger, R., et al. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703253 · Cited by 70 · see citing works
Bird, J. M., Russell, N., & Samson, D. (1993) · PubMed · Cited by 67 · see citing works
Autologous stem cell transplantation for relapsed and primary refractory myeloma
Rajkumar, S. V., Fonseca, R., Lacy, M., Witzig, T., Lust, J., Greipp, P., Therneau, T., Kyle, R. A., Litzow, M., & Gertz, M. A. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701805 · Cited by 66 · see citing works
Self-citationPowles, R., Raje, N. S., Milan, S., et al. (1997) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1700917 · Cited by 64 · see citing works
Cavo, M., Bandini, G., Benni, M., et al. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701280 · Cited by 63 · see citing works
Nadal, E., Giné, E., Bladé, J., Esteve, J., Rosiñol, L., Fernández‐Avilés, F., Marı́n, P., Martı́nez, C., Rovira, M., Urbano-Ispizúa, Á., et al. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704313 · Cited by 59 · see citing works
Self-citationSalmon, S. E., Tesh, D. W., Crowley, J., et al. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1575 · Cited by 58 · see citing works
Bladé, J., Esteve, J., Rives, S., et al. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702622 · Cited by 52 · see citing works
Self-citationTreatment of myeloma using intensive therapy and allogeneic bone marrow transplantation.
De, R., Jd, S., Hg, K., et al. (1995) · PubMed · Cited by 50 · see citing works
Ten-Year Survival in Multiple Myeloma
Alexanian, R. (1985) · Archives of Internal Medicine · doi:10.1001/archinte.1985.00360110149029 · Cited by 48 · see citing works
Allogeneic Stem Cell Transplantation for Multiple Myeloma
Bensinger, W. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.06.001 · Cited by 45 · see citing works
Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma
Gertz, M. A., Lacy, M., Inwards, D., et al. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702445 · Cited by 40 · see citing works
Self-citationMarit, G., Fabères, C., Pico, J. L., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1306 · Cited by 32 · see citing works
Hjorth, M., Holmberg, E. C., Rödjer, S., et al. (1999) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1999.tb01757.x · Cited by 30 · see citing works
Dyson, P. G., Horvath, N., Joshua, D. E., et al. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702408 · Cited by 30 · see citing works
Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts
Vesole, D., Simic, A., & Lazarus, H. M. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703254 · Cited by 13 · see citing works
Self-citationSchmoor, C., & Schumacher, M. C. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006111821492 · Cited by 11 · see citing works
Flagged first, then by citations
Research works printed but not linked: 16
- [2]2. Blade ´ J, San Miguel JF, Fontanillas M, et al. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two trials including 914 patients. Hematol J, 2001;2:272-278.
- [18]18. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97.
- [19]19. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous - transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789-793.
- [21]21. Palumbo A, Triolo S, Argentino C, et al. Dose-intensive melphalan with stem cell support (MEL 100) is superior to standard treatment in elderly myeloma patients. Blood. 1999;94:1248-1253.
- [25]25. Blade ´ J, Sureda A, Ribera JM, et al. High-dose therapy autotransplantation/ intensification vs continued conventional chemotherapy in multiple myeloma responding to the initial treatment. Results of a prospective randomized trial from the Spanish cooperative group PETHEMA [abstract]. Blood. 2001; 98:815a.
- [36]36. Cavo M, Tosi P, Zamagani E, et al. The 'Bologna 96' clinical trial of single vs. double autotransplant for previously untreated multiple myeloma patients [abstract]. Blood. 2002;100:179a.
- [37]37. Segeren CM, Sonneveld P, Van der Holt B, et al. Myeloablative treatment following intensified chemotherapy in previously untreated multiple myeloma: a prospective randomized phase III study [abstract]. Blood. 2001;98:815a.
- [46]46. Moreau P, Misbahi R, Milpied N, et al. Long-term results (10 years) of highdose therapy in 127 patients with de novo multiple myeloma [abstract]. Blood. 2001;98:684a.
- [47]47. Anderson KC, Shaughnessy JD, Barlogie B, et al. Multiple myeloma. In: Hematology 2002: American Society of Hematology Education Program Book. Washington, DC: American Society of Hematology; 2002:214-240.
- [48]48. Corradini P, Voena C, Tarella C, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation. J Clin Oncol. 1999;17:208-215.
- [65]65. Peggs KS, Williams CD, Chopra R, et al. Non-myeloablative allogeneic transplantation with adjuvant dose escalated donor lymphocyte infusions for multiple myeloma [abstact]. Blood. 2000;96:781a.
- [67]67. Maloney DG, Sahebi F, Stockerl-Goldstein KE, et al. Combining an allogeneic graft vs. myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma [abstract]. Blood. 2001;98:434a.
- [71]71. Reece DE, Vesole D, Flomenberg N, et al. Intensive therapy with high-dose melphalan (MEL) 280 mg/m 2 plus amifostine cytoprotection and ASCT as part of initial therapy in patients with multiple myeloma [abstract]. Blood. 2002;100: 432a.
- [72]72. Powles R, Sirohi B, Treveleaven J, et al. Continued first complete remission in multiple myeloma for over 10 years: a series of 'operationally cured' patients [abstract]. Blood. 2000;96:515a.
- [75]75. Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. Blood. 1994;84:4278-4282.
- [77]77. Reece DE, Perez WS, Bredeson CN, et al. Autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients < 60 vs ≥ 60 years (yrs) of age [abstract]. Blood. 2001;98:684a.
Cited by
Sorted by citations
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534 · see citing works
Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2011) · American Journal of Hematology · doi:10.1002/ajh.21913 · Cited by 152 · see citing works
- Authors
- Bladé, J., Vesole, D. H., & Gertz, M. A.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2003-11-15
- Volume
- 102
- Issue
- 10
- Pages
- 3469-3477
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2083814475
- Semantic Scholar
- 7187b0c3679e53a779d76d6c5e5f68b30b9cc4ea
- Cited by
- 88
- References
- 70
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 2 · 2018: 2 · 2017: 1 · 2016: 4 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 1
- FWCI
- 5.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, hematopoietic stem cell transplantation, timing of transplantation, transplant selection, post-transplant relapse
- MeSH terms
- Humans, Multiple Myeloma, Remission Induction, Transplantation, Autologous, Transplantation, Homologous, Treatment Outcome, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
